HK Stock Market Move | NANHUA FUTURES (02691) rises more than 10%, the company's overseas business advantages are obvious.
Nanhua Futures Co., Ltd. (02691) rose more than 10%, at the time of writing, up 10.28%, at 11.69 Hong Kong dollars, with a transaction volume of 49.5043 million Hong Kong dollars.
Nanhua Futures (02691) rose more than 10%, at the time of publication, up by 10.28%, at HKD 11.69, with a turnover of HKD 49.5043 million.
On the news front, Guotai Haitong pointed out that Nanhua Futures' overseas business has a clear first-mover advantage, and the Hong Kong stock IPO opens up the business ceiling. Nanhua Futures' overseas platform Hanghua International is a key source of the company's profits. Since 2007, the company has continuously obtained relevant derivative trading and clearing licenses, forming a strong uniqueness among domestic futures companies. The expansion of overseas derivative business is essentially constrained by capital. The company's Hong Kong stock IPO fills the capital base needed for the expansion of overseas business, thus transforming the "first-mover license advantage" into a "scalable advantage."
Earlier on February 9, Nanhua Futures announced that all net proceeds from the global offering of H shares will be used for the capital increase of its overseas subsidiary Hanghua International, with an increase amount of HKD 1.203 billion, converted at the middle rate of RMB exchange rate published by the People's Bank of China on February 6, 2026, approximately RMB 1.072 billion. Currently, Hanghua International's registered capital is HKD 826 million, and after the capital increase, its registered capital will reach HKD 2.029 billion.
Related Articles

HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.
HK Stock Market Move | INNOCARE (09969) rose by more than 4% in the final trading session, completion of patient enrollment in Phase III clinical trial of BCL2 inhibitor combined with Apatinib.

Citibank: The budget confirms that the scope of Hong Kong's economic recovery will expand, with fiscal reserves expected to remain stable.

Caitong: Maintains "Buy" rating on TRIP.COM-S (09961) Performance exceeds expectations and internationalization drive continues.

RECOMMEND

Robot Concept Hong Kong Stocks Retreat After Spring Gala Rally As 2026 Emerges As Pivotal Year For Mass Production And Commercialization
25/02/2026

Hong Kong IPO Fundraising Surges Tenfold At Start Of Year As 110 A‑Share Companies Queue For Listings
25/02/2026

AI Iteration Risks Surface As Hong Kong Market Diverges; Low‑Valuation, High‑Dividend Legacy Stocks Attract Capital As Safe Havens
25/02/2026


